In conversations about sterilization, manufacturers are often presented with the idea that one modality is clearly superior to the others. In practice, that framing is rarely helpful.
The truth is that there is no perfect sterilization technology.
Every modality has drawbacks. Some relate to material compatibility. Others relate to regulatory pressures, operational constraints, infrastructure limitations, or economics. What works extremely well for one product may be completely unsuitable for another. The real decision is about identifying which set of tradeoffs makes the most sense for a specific product, manufacturing process, and supply chain.
Put another way, every sterilization technology has some version of “suck.” The goal is simply to choose the one that introduces the fewest problems for your product.
Below is a high-level look at how the major modalities compare.
Proven, Widely Accepted, But Dependent On Cobalt Supply
Gamma irradiation has been a foundational sterilization technology for decades. It offers several advantages that have made it a mainstay of the medical device industry, particularly for products that require deep penetration and well-understood regulatory precedent.
Manufacturers often choose gamma for reasons such as:
- Strong penetration through dense products and low (good) dose uniformity ratio performance
- Long regulatory history and extensive validation data
- Stable, well-understood processing environments
However, gamma also carries structural constraints that are difficult to ignore.
First, the technology depends on cobalt-60, a radioactive isotope produced in a limited number of nuclear reactors worldwide. Production capacity, reactor outages, and geopolitical dynamics can all influence the availability and price of cobalt. Additionally, the long production time (2-4.5y depending on source), combined with an inability to “stock” Co-60 means it can be difficult to match supply to demand. Over the past decade, the industry has already seen significant price increases tied to these supply realities – and it certainly will in the future.
Second, gamma’s slower dose rate typically requires many hours of radiation exposure. This extended period in a high-radiation environment can cause material compatibility challenges (driven by the extended time in a highly oxidative environment) for certain polymers and medical device components. In some cases this leads to discoloration, embrittlement, or mechanical property changes that require additional testing or reformulation.
For many products, gamma remains an excellent sterilization modality. But manufacturers need to recognize that its long-term economics and supply chain stability are tied directly to cobalt availability.
Extremely Flexible, But Facing Regulatory And Cost Pressure
Ethylene oxide has historically been the most versatile sterilization modality available to medical device manufacturers. Its ability to sterilize many delicate materials and complex geometries offers wide compatibility with many devices. Historically, it has also been relatively inexpensive.
These characteristics allow EO to offer high performance and value, and explain why EO has played such a large role in the global sterilization infrastructure.
Typical advantages of EO include:
- Compatibility with heat-sensitive materials
- Ability to sterilize complex devices with long lumens or intricate geometries
- Deep penetration into packaging and product assemblies
At the same time, EO is operating in a regulatory environment that has changed significantly over the past several years.
Environmental and community exposure concerns have led to increased scrutiny of EO facilities, particularly in the United States. As a result, sterilization providers across the industry have invested heavily in emissions control technologies, facility upgrades, and monitoring infrastructure to comply with evolving regulatory expectations. Additionally and unfortunately, we estimate that at least $1.5 billion to date has been spent on legal settlements and in defending lawsuits.
Between site environmental control upgrades and legal defense, we estimate that the EO industry has spent at least $2 billion in the US over environmental concerns.
Those investments do not disappear. Over time, they become part of the cost structure of EO sterilization and ultimately flow through the supply chain to manufacturers. Perhaps most concerning is that this situation is creating a world in which only large providers can afford to play – reducing the number of EO sterilization options available to customers and ultimately limiting the competitiveness of the market.
EO remains an essential modality and will continue to play a major role in sterilization. However, manufacturers should expect the economics of EO to evolve as regulatory pressures reshape the industry.
Fast And Efficient, But Product-Specific
Electron beam sterilization addresses many of the challenges associated with both gamma and EO. Because E-Beam systems use electricity rather than radioactive isotopes or chemical gases, they avoid the supply and environmental complications associated with other modalities.
E-Beam processing offers operational advantages that are attractive for many customers. For example:
- Sterilizing doses can be delivered in seconds rather than hours, accelerating throughput
- No radioactive sources are required
- E-Beam is as environmentally-friendly as the electricity it consumes. For example, NextBeam’s South Dakota facility runs on ~84% renewable electricity.
- For the right products (typically lower-density medical devices), E-Beam can often be by far the most economical solution.
However, E-Beam also comes with its own set of downsides and risks.
Electron penetration is more limited than gamma radiation, which is photon-based. This means that product density, packaging configuration, and orientation must be carefully evaluated upfront for compatibility with E-Beam. Certain product designs may require additional dose mapping work or packaging adjustments to ensure uniform sterilization. Dose mapping – demonstrating that the packaged final product is dose within tolerance – is typically more challenging than gamma dose mapping for certain types (typically high density or low dose range) of product. The best news here is that these limitations are knowable and addressable upfront and do not present continuing risk.
Additionally, accelerator systems require skilled operation and maintenance to maintain consistent performance and uptime, and certain components can fail unpredictably, rendering the E-Beam system out of service, in some cases, for days while the failure is identified, remedied, and the system is re-validated.
For products that are compatible with the physics of electron beam processing, E-Beam can be an extremely efficient sterilization method. But as with any modality, it is not universally applicable.
Sterilization Decisions Are Systems Decisions
The biggest mistake manufacturers can make is evaluating sterilization modalities in isolation.
Sterilization sits within a much larger system that includes:
- Product materials and component selection
- Packaging design and density
- Manufacturing throughput requirements
- Regulatory strategy and validation pathways
- Long-term supply chain resilience
A sterilization technology that appears optimal on paper may introduce challenges elsewhere in the system.
For that reason, the best sterilization decisions are made when manufacturers step back and evaluate the full context of the product and its lifecycle.
Choose The Tradeoffs That Fit Your Product
Gamma, EO, and E-Beam are all highly effective sterilization technologies. Each one has enabled decades of safe medical device manufacturing.
But none of them are perfect:
- Gamma involves dependence on cobalt supply and radiation-related material considerations.
- EO faces increasing regulatory pressure and infrastructure costs.
- E-Beam introduces product-specific engineering constraints tied to electron penetration and packaging density, and E-Beam accelerators may suffer unpredictable downtime.
The right sterilization strategy usually becomes clear once the product, packaging, and supply chain realities are on the table.
If you are evaluating sterilization pathways for a new device, a modality transition, or simply trying to understand your options, our team is always happy to talk through the tradeoffs.
You can schedule a conversation with the NextBeam team, here.
Additional Articles We Think You Might Like
Have a question? Speak with a sterilization expert today, at your own convenience.
